Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. Its clinical studies and product development design includes TeloView SMM, TeloView Test to Predict Patient Resistance to Treatment, development in collaboration with the Mayo Clinic and TeloView Test to monitor minimal residual disease in MM patients. The Company, by combining quantitative analysis of three-dimensional telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.


TSXV:TELO - Post by User

Bullboard Posts
Comment by gooddogon Mar 15, 2017 7:36pm
177 Views
Post# 25985302

RE:RE:RE:take a break

RE:RE:RE:take a break
jammingthepipeline wrote:

I understand what you are saying.  But what I find annoying is the very low volume what translates in a lack of interest in this company. Anyway, we are 10% lower than the last PP and still no bids.

 



JTP, as great a diagnostic tool that 3D is, it is still just software. It needs a partner, jv, buy out from someone who will use the software in real time. Somebody like Johnson and Johnson or Roche need to step up and take 3D to the next level

Bullboard Posts